Exenatide News and Research

RSS
Exenatide (marketed as Byetta) is one of a new class of medications (incretin mimetics) approved for the treatment of diabetes mellitus type 2.
Clinical trial to examine effectiveness of diabetes drug to slow or stop progression of Parkinson's

Clinical trial to examine effectiveness of diabetes drug to slow or stop progression of Parkinson's

GLP-1 receptor agonist may benefit high-risk diabetes

GLP-1 receptor agonist may benefit high-risk diabetes

New clinical trial focuses on respiratory drug ambroxol for treatment of Parkinson's disease

New clinical trial focuses on respiratory drug ambroxol for treatment of Parkinson's disease

New class of diabetes drugs differs in efficacy and safety profiles, shows new research

New class of diabetes drugs differs in efficacy and safety profiles, shows new research

Columbia University data scientists create world's first catalog of therapeutic venom

Columbia University data scientists create world's first catalog of therapeutic venom

Oral formulation of insulin shows promise in management of blood glucose in diabetic rats

Oral formulation of insulin shows promise in management of blood glucose in diabetic rats

AstraZeneca presents safety and efficacy data for ExQW at 51st Annual Meeting of EASD

AstraZeneca presents safety and efficacy data for ExQW at 51st Annual Meeting of EASD

Intarcia Therapeutics announces positive top-line results from ITCA 650 Phase 3 FREEDOM-2 clinical trial

Intarcia Therapeutics announces positive top-line results from ITCA 650 Phase 3 FREEDOM-2 clinical trial

Study shows how GLP-1 receptor agonists modify the brain's response to food

Study shows how GLP-1 receptor agonists modify the brain's response to food

Results from Intarcia's two phase 3 clinical trials of ITCA 650 to be presented at ADA's Scientific Session

Results from Intarcia's two phase 3 clinical trials of ITCA 650 to be presented at ADA's Scientific Session

Intarcia Therapeutics announces closing of $225 million synthetic royalty financing

Intarcia Therapeutics announces closing of $225 million synthetic royalty financing

Transition Therapeutics begins TT-401 Phase 2 clinical study for treatment of type 2 diabetes

Transition Therapeutics begins TT-401 Phase 2 clinical study for treatment of type 2 diabetes

Patients with Parkinson's disease show improvements after exenatide therapy

Patients with Parkinson's disease show improvements after exenatide therapy

Oramed to present detailed results from ORMD-0801 Phase 2a trial at 2014 GTC Diabetes Summit

Oramed to present detailed results from ORMD-0801 Phase 2a trial at 2014 GTC Diabetes Summit

Oramed Pharmaceuticals' ORMD-0801 Phase 2a study meets primary and secondary endpoints

Oramed Pharmaceuticals' ORMD-0801 Phase 2a study meets primary and secondary endpoints

Oramed to publish results of Phase 2a clinical trial for oral insulin capsule for treatment of type 2 diabetes

Oramed to publish results of Phase 2a clinical trial for oral insulin capsule for treatment of type 2 diabetes

Oramed Pharmaceuticals to purchase $15,800,000 shares in registered direct offering

Oramed Pharmaceuticals to purchase $15,800,000 shares in registered direct offering

Oramed reports positive results from ORMD-0801 pharmacokinetic study in type 1 diabetes patients

Oramed reports positive results from ORMD-0801 pharmacokinetic study in type 1 diabetes patients

Bristol-Myers Squibb signs agreement to sell global diabetes business

Bristol-Myers Squibb signs agreement to sell global diabetes business

Oramed starts patient recruitment in Israel for ORMD-0801 clinical trial for patients with T1DM

Oramed starts patient recruitment in Israel for ORMD-0801 clinical trial for patients with T1DM